The primary purpose of the study is to assess whether SAM-531, an investigational drug, is safe and well tolerated, compared with placebo (a medically inactive substance), in subjects with mild to moderate Alzheimer's disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
QUADRUPLE
Enrollment
72
Unnamed facility
Delray Beach, Florida, United States
Unnamed facility
Hallandale, Florida, United States
Unnamed facility
St. Petersburg, Florida, United States
Unnamed facility
Atlanta, Georgia, United States
Routine safety and tolerability will be evaluated.
Time frame: 28 days
This study will also investigate the pharmacokinetics(PK, how the drug is metabolized) and pharmacodynamics (PD, how the drug affects bodily and mental function) of SAM-531 compared to placebo.
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Long Branch, New Jersey, United States
Unnamed facility
New York, New York, United States
Unnamed facility
Bennington, Vermont, United States